Tvardi Therapeutics
TVRD
114 hedge funds and large institutions have $296M invested in Tvardi Therapeutics in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 11 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
130% more capital invested
Capital invested by funds: $129M → $296M (+$167M)
24% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 29
13% more funds holding
Funds holding: 101 → 114 (+13)
0.31% more ownership
Funds ownership: 1.41% → 1.72% (+0.31%)
25% less call options, than puts
Call options by funds: $11.2M | Put options by funds: $15.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.6M |
| 4 |
RCP
Rho Capital Partners
New York
|
+$7.42M |
| 5 |
Jennison Associates
New York
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$2.07M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.93M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.69M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$1.56M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.34M |
TVRD Hedge Fund Activity: Q1 2017 in Review
114 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2017, worth a combined $296M — up 130% from $129M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TVRD positions and 11 closed out — a net gain of 20 holders — while 36 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $20.9M. The largest seller was Allianz Asset Management, cutting an estimated $2.07M.
- 114 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2017, up from 101 in Q4 2016.
- Funds reported $296M of Tvardi Therapeutics stock for Q1 2017, up 130% quarter-over-quarter.
- 31 funds opened new Tvardi Therapeutics positions in Q1 2017 and 11 closed out, a net change of +20 holders.
- The largest Tvardi Therapeutics buyer in Q1 2017 was BlackRock, an estimated $20.9M added.
- The largest Tvardi Therapeutics seller in Q1 2017 was Allianz Asset Management, an estimated $2.07M sold.
Based on aggregated 13F filings for Q1 2017.